Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Large Growth in Short Interest

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 4,820,000 shares, a growth of 8.6% from the December 15th total of 4,440,000 shares. Based on an average daily trading volume, of 400,900 shares, the days-to-cover ratio is currently 12.0 days. Approximately 19.6% of the shares of the company are short sold.

Institutional Investors Weigh In On Arcturus Therapeutics

Large investors have recently made changes to their positions in the company. Franklin Resources Inc. boosted its stake in Arcturus Therapeutics by 54.6% during the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock valued at $2,412,000 after buying an additional 36,714 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Arcturus Therapeutics by 45.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock valued at $52,819,000 after acquiring an additional 712,650 shares during the last quarter. Empire Life Investments Inc. purchased a new position in shares of Arcturus Therapeutics in the third quarter valued at $3,498,000. XTX Topco Ltd bought a new stake in Arcturus Therapeutics in the second quarter worth $596,000. Finally, Squarepoint Ops LLC purchased a new stake in Arcturus Therapeutics during the second quarter valued at $718,000. 94.54% of the stock is owned by institutional investors.

Arcturus Therapeutics Trading Down 1.3 %

NASDAQ ARCT opened at $16.79 on Friday. The business’s fifty day moving average is $17.46 and its 200 day moving average is $19.85. Arcturus Therapeutics has a fifty-two week low of $14.30 and a fifty-two week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $41.67 million during the quarter, compared to the consensus estimate of $49.16 million. During the same period in the previous year, the company posted ($0.61) EPS. As a group, equities research analysts predict that Arcturus Therapeutics will post -2.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ARCT has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $66.75.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.